The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.
Completed · Phase 3
Conditions studied: Bone Marrow Stem Cell Transplant
In brief
This study is being done in stem cell transplant recipients to see if taking the drug valganciclovir can prevent or reduce serious cytomegalovirus (CMV) infections that can occur 100 days or later after transplant.
Key facts
- Study ID
- NCT00275665
- Run by
- Mayo Clinic
- People needed
- 20
- Starts
- 2001-11-01
- Expected to finish
- 2007-07-01
- Last updated by the study team
- 2011-12-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.